赛诺菲收购阿尔茨海默症药物开发商Vigil Neuroscience

新浪财经
22 May

法国制药巨头赛诺菲(Sanofi)周三宣布已达成协议,以约4.7亿美元的价格收购Vigil Neuroscience,该交易为赛诺菲的阿尔茨海默症治疗增加了一种新的研究药物。两家公司周三表示,赛诺菲将以每股8美元的前期付款收购Vigil所有已发行股票。Vigil的股东还将获得每股2美元的额外现金,如果在规定期限内实现了正在开发的阿尔茨海默症治疗药物的首次商业销售。包括可能的后续支付在内,这笔交易的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10